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Abstract  
 
Objective: Reliable assessment of cognitive functions is a challenging task in 
amyotrophic lateral sclerosis (ALS) patients unable to speak and write. We therefore 
present an eye-tracking based neuropsychological screening tool based on the 
Edinburgh Cognitive and Behavioural ALS Screen (ECAS), a standard screening tool 
for cognitive deficits in ALS. 
Methods: In total, 46 ALS patients and 50 healthy controls matched for age, gender 
and education were tested with an oculomotor based and a standard paper-and-
pencil version of the ECAS.  
Results: Significant correlation between both versions was observed for ALS patients 
and healthy controls in the ECAS total score and in all of its ALS-specific domains (all 
r > 0.3; all p < 0.05). The eye-tracking version of the ECAS reliably distinguished 
between ALS patients and healthy controls in the ECAS total score (p < 0.05). Also, 
cognitively impaired and non-impaired patients could be reliably distinguished with a 
specificity of 95%.  
Conclusion: This study provides first evidence that the eye-tracking based ECAS 
version is a promising approach for assessing cognitive deficits in ALS patients who 
are unable to speak or write. 
 
 
Keywords: Eye-tracking; Cognition; Edinburgh Cognitive and Behavioural ALS 
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Introduction 
 
It is well recognized that cognitive deficits play a prominent role in amyotrophic lateral 
sclerosis (ALS) with about 30% of patients exhibiting impairment, mostly in the 
domains of language, verbal fluency and executive function (1-3). These deficits in 
addition to changes in behavior like disinhibition or apathy which also occur in a small 
subset of ALS patients (2) are associated with carer burden (4), survival (5) and 
decision making regarding life-shortening and prolonging measures (6-8). Therefore, 
a regular valid assessment of cognitive functioning, especially in the context of 
clinical scenarios in which decisional capacity is of utmost importance, is essential in 
the course of the disease (9).  
The Edinburgh Cognitive and Behavioural ALS Screen (ECAS) is a widely used and 
well validated tool to screen for potential cognitive deficits among ALS patients in the 
domains of memory, visuospatial perception, language, verbal fluency and executive 
function as well as for behavioral changes (10,11). It is adapted to motor impairment, 
as it can be performed in a written or oral manner. However, in more advanced 
stages when patients lose the ability to speak or write, other techniques are needed. 
One promising approach is based on eye movements. Even though oculomotor 
impairments may occur in some patients in the course of ALS (12-14), for many 
patients it still has the potential to be a valuable tool in the detection of cognitive 
deficits. Previous studies have already proven the applicability of this approach for 
ALS patients (15-18), using different tasks of executive functioning and devices which 
require a stationary testing environment. Yet, a mobile version of a cognitive 
screening tool specifically designed for bedside use in ALS patients is still lacking. 
Therefore, the goal of this study was to provide a proof of concept for a mobile eye-
tracking screening tool based on the ECAS and to demonstrate its usefulness and 
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applicability in a sample of ALS patients. We hypothesized that the eye-tracking 
version is suitable to assess ALS patients’ cognitive performance and to robustly 
identify those with relevant impairment. 
 
 
Materials and Methods 
 
Participants 
The study was approved by the Ethics Committee of the University of Ulm 
(Reference No. 19/12) and was performed in accordance with the ethical standards 
laid down in the 1964 Declaration of Helsinki and its later amendments. All 
participants gave written informed consent to the study. Initially, 50 patients 
diagnosed with ALS according to the revised El-Escorial criteria (19) were recruited 
from the in- and outpatient clinic of the Department of Neurology, University of Ulm, 
Germany. An additional group of 50 healthy controls (HC) matched for age, gender 
and education was used for comparison. None of the participants had a history of 
any major psychiatric or neurological condition (other than ALS) and all subjects had 
normal or corrected to normal vision.  
All patients were able to complete the paper-and-pencil ECAS version. However, due 
to insufficient control over the eye-tracking device, which was not due to ALS-
dependent oculomotor impairments but rather discomfort with the unfamiliar 
technique, oculomotor recording was not possible in two patients. Additionally, one 
patient was not able to complete the eye-tracking based ECAS due to difficulties in 
task comprehension, whereas another wished to abort the experiment because of 
fatigue. Therefore, data of n = 46 patients were included in the final analyses. 
Patients’ physical impairment was assessed using the ALS functional rating scale 
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revised version (ALS-FRS) (20), affective state was measured with the ALS 
Depression Inventory 12 (ADI-12) (21) and the proposed clinical ALS disease staging 
system from Roche et al. (22) was used for further patient characterization. For 
detailed sample characteristics see Table 1. 
 
Design 
A pseudo-randomized study design similar to the one previously reported by Keller et 
al. 2015 (16) was used: To avoid sequence effects, patients and HC were each 
subdivided into two age- gender- and education-matched groups. One group 
completed the German paper-and-pencil ECAS version (23) according to standard 
procedures first, followed by the eye-tracking based version, whereas the other group 
did vice versa. Testing was scheduled to take place on the same day.  
 
Eye-tracking based ECAS 
To reduce fatiguing testing time and to make the eye-tracking based version suitable 
for oculomotor control, the German ECAS version from Lulé et al., 2015 (23) was 
modified, incorporating all five original domains (ALS-non-specific: memory, 
visuospatial perception; ALS-specific: language, verbal fluency and executive 
function). Detailed information about this version can be found in Table 2.  
Tasks were displayed on a PC presentation screen, whereas the participants gave 
their answers by directing their gaze on a separate notebook screen displaying a 
matrix composed of numbers 0 to 9 and all letters of the German alphabet. Fixation 
of gaze for 1000 ms on a number or letter initialized selection of this item. 
Participants’ eye movements were registered using the commercially available 
EyeTribe® system (The Eye Tribe Aps, Copenhagen, Denmark) connected to the 
notebook on which the matrix was displayed. Their choice was subsequently 
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recorded by in-house written software and displayed above the matrix (Figure 1). 
Following each selection, subjects had the possibility to correct their choice or were 
asked to confirm their answers for every question of the eye-tracking based ECAS. 
All answers were recorded on a separate sheet of paper by the experimenter and 
later used for calculating each subject’s domain-specific and total eye-tracking based 
ECAS score (Table 2).  
 
Statistical analysis 
Data were a priori analyzed for normal distribution using the Kolmogorov-Smirnov 
test. In order to detect group differences between ALS patients and HC, Mann-
Whitney U tests and, where appropriate, Pearson’s chi-squared tests were used. 
Spearman-Rho correlation analyses were used to determine correlation coefficients 
between the two versions. A median split on patients’ overall ECAS score in the 
standard version was performed to compare cognitively more and less impaired 
patients in the eye-tracking version. Also, performance accuracy of ALS patients and 
HC was calculated for both versions. All analyses were performed using IBM® SPSS 
Version 21.0, two-sided and the significance level was set at p < 0.050. 
 
 
Results 
 
Group comparisons 
In the standard version of the ECAS, ALS patients performed significantly worse than 
HC in the ALS-specific domains of verbal fluency (p = 0.002), executive function (p = 
0.014) and in the overall score (p = 0.001). In the eye-tracking version of the ECAS 
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they performed significantly worse in the executive function domain (p = 0.007) and 
in the overall score (p = 0.030) (Table 1).  
The median of patients’ overall performance accuracy was 82% in the standard 
version of the ECAS and 83% in the eye-tracking version. For HC it was 89% in the 
standard version and 87% in the eye-tracking version, respectively. ALS patients’ 
scores did not significantly differ between testing modalities in the ECAS overall 
score and any of its domains except verbal fluency (p = 0.001). For HC there was no 
difference in scores of any ECAS domain or the total score between testing 
modalities. 
The comparison between high and low performing patients as determined by the 
median split based on patients’ overall ECAS score in the standard version revealed 
a significant group difference in the executive function domain (p = 0.007) but no 
significant difference in the ECAS overall score (p = 0.090) of the eye-tracking 
version.  
 
Correlation analyses 
In the patient sample, Spearman-Rho correlation analyses revealed a statistically 
significant congruence between results in the standard and eye-tracking version of 
the ECAS in the domains of visuospatial perception (r = 0.379; p = 0.009), language 
(r = 0.728; p < 0.001), verbal fluency (r = 0.313; p = 0.034), executive function (r = 
0.520; p < 0.001) and in the total score (r = 0.393; p = 0.007) (Figure 2A & 2C). In the 
memory domain however, this correlation was still acceptable but did not reach the 
threshold for statistical significance (r = 0.288; p = 0.052). Similar correlations 
between the standard and eye-tracking version of the ECAS were also found in the 
HC sample in all domains (memory (r = 0.322; p = 0.023), visuospatial perception (r = 
0.374; p = 0.007), language (r = 0.543; p < 0.001), verbal fluency (r = 0.473; p = 
8 
 
0.001), executive function (r = 0.645; p < 0.001)) and in the total score (r = 0.602; p < 
0.001) (Figure 2B & 2D). There was no statistically significant association between 
physical impairment as measured by the ALS-FRS and patients’ cognitive 
performance in both ECAS versions as well as between their depressiveness as 
assessed by the ADI-12 and their performance in any domain of the two versions. 
 
Specificity and sensitivity  
Using a cut-off score for cognitive impairment in ALS patients, determined according 
to the ECAS guidelines by Abrahams et al. 2014 (10), a specificity of 95% and a 
sensitivity of 50% were found for the total score of the eye-tracking version of the 
ECAS. For the language domain of this version, specificity was 100% and sensitivity 
80%. In the verbal fluency domain, specificity was 100% and sensitivity 50%, and in 
the executive function domain, specificity and sensitivity were 98% and 33%, 
respectively.  
 
 
Discussion 
 
This study shows the feasibility and reliability of a mobile eye-tracking screening tool 
based on the ECAS which can be easily administered even at the patient’s bedside 
in a time frame of usually less than one hour. As in previous studies with healthy 
subjects (15,24,25) and ALS patients (16), there was a strong association between 
performance in both modalities of cognitive testing (oculomotor and paper-and-
pencil) with satisfying correlations between scores in all relevant domains of both 
versions of the ECAS in the healthy control and in the patient sample.  
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Results obtained with the eye-tracking based ECAS version also allowed to 
distinguish between patients and healthy controls in the domain of executive function 
and in the ECAS total score as well as between more and less cognitively impaired 
patients in the executive function domain. However, there was no significant 
difference between ALS patients and healthy controls in the other ALS-specific 
domains (language and verbal fluency). For the language domain this is not 
surprising, as in this sample there was no group difference in the standard version of 
the ECAS either. For the verbal fluency task however, in which patients performed 
significantly worse than healthy controls in the standard ECAS, this might be due to 
the testing modality: During spelling of one word with the eyes, subjects might 
additionally find time to imagine the next word already; but it could also be explained 
by the applied changes compared to the original ECAS, i.e. using only the restricted 
word generating task with subsequent weighting to reduce fatiguing testing time.  
This, of course, can be generalized to all domains that required amendments for 
oculomotor based testing. Specifically, the reduction of items in the language and 
verbal fluency domain might hamper comparability between both modalities. Yet, 
using all items of the standard ECAS would have resulted in a too time consuming 
and tedious oculomotor testing, which made this tradeoff between elaborateness and 
usability necessary. To increase the reliability of the eye-tracking paradigm we 
introduced weighting factors which ensure a score distribution equal to that of the 
standard ECAS. Given these issues, alternative approaches to assess potential 
deficits in these patients could use more simplistic, domain-specific tasks (18). 
However, our goal was to implement an oculomotor based screening tool 
encompassing a broad range of potential cognitive deficits associated with ALS and 
not a diagnostic instrument for one specific cognitive task only.  
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The very high specificity observed in the most relevant cognitive domains and in the 
ECAS total score provides evidence that the eye-tracking based ECAS version is well 
suited to identify those ALS patients with substantial cognitive impairment. Yet, the 
price for this high specificity is a rather low sensitivity and the accompanying higher 
risk for potential type II errors in some domains of this version. Whereas this 
screening instrument therefore seems to have a very low rate of false positive results, 
caution should be applied with regard to potential false negative results. Again, this 
can be tolerated as the main focus of this eye-tracking based screening tool is to 
identify those ALS patients with severe cognitive impairment. 
Due to the nature of this proof-of-principle study, no far advanced ALS patients were 
included. Even though cognitive impairment seems to be stable during the course of 
the disease (26,27) and even may precede motor symptoms (28), further studies are 
needed to investigate the cognitive status of ALS patients in advanced stages of the 
disease. Despite using a balanced pseudo-randomized order in our study design, 
there might also have been some learning effects, potentially distorting the results of 
both versions in the memory and verbal fluency domain. However, for our purposes 
this could not have been avoided. Another limitation of this approach certainly is that 
patients are required to still have sufficient eye movement control. Yet, studies have 
reported abnormalities in oculomotor control in the course of ALS (12,14,29) which 
may, especially in far advanced patients due to extended alterations in neural 
networks (30), lead to a complete loss of voluntary eye movements in the final stages 
of ALS. Future work in this field could therefore focus on developing tools based on 
brain-computer-interface control, a promising technique whose usability for these 
ALS patients has already been demonstrated in previous studies (31,32), to reliably 
assess cognitive functioning in far advanced patients (33). However, above 
mentioned considerations regarding the translation of standard neuropsychological 
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screening instruments into an eye-tracking format also apply when this modality of 
testing will be used. Furthermore, a more thorough psychometric validation of a 
specific eye-tracking version of the ECAS in a sample of healthy participants is 
needed to establish this tool for use outside research paradigms.  
In conclusion, this approach provides support that eye-tracking based techniques can 
be used as a fast and reliable method for cognitive assessment of patients unable to 
speak and write based on the ECAS, an established neuropsychological screening 
tool specifically designed for ALS, which in its standard form has already been well 
validated and widely used in different cultures and languages (10,19,34,35). 
Considering the fact that information about the cognitive status of ALS patients plays 
a crucial role in the context of therapeutic interventions and end-of-life decision 
making (6,7,9), the importance of ALS-specific hand- and speech-motor-free 
cognitive testing becomes even more apparent. 
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Figure 1: Illustration of the eye-tracking version of the Edinburgh Cognitive and 
Behavioural ALS Screen (ECAS) 
 
Setup of the eye-tracking version of the ECAS including the presentation screen, on 
which the current task is displayed, and the main screen, on which the matrix to write 
the answer, composed of numbers 0 to 9 and all letters of the German alphabet, is 
presented. Participants’ eye movements are registered by the EyeTribe® device. A 
letter or number on the matrix is selected by fixating the target for 1000 ms. 
 
 
Figure 2: Correlations between performance scores of the standard and the eye-
tracking based version of the Edinburgh Cognitive and Behavioural ALS Screen 
(ECAS)  
 
Shown are the total scores of the eye-tracking (ECAS ET) and the standard (ECAS 
STD) version of the ECAS (top row) for ALS patients (A; green) and healthy controls 
(B; blue) as well as the executive function scores of both versions (bottom row) for 
patients (C; green) and healthy controls (D; blue). Additionally, the correlation 
coefficient r, as determined by Spearman-Rho correlation analyses, is given.  
